Cabazitaxel

證據等級: L5

預測適應症: 10 個

Cabazitaxel: From Metastatic Castration-Resistant Prostate Cancer to Female Breast Carcinoma

One-Sentence Summary

Cabazitaxel is a third-generation semisynthetic taxane, originally approved (in combination with prednisone) for metastatic castration-resistant prostate cancer after docetaxel failure. The TxGNN model predicts it may be effective for Female Breast Carcinoma, with currently 0 registered clinical trials in the ClinicalTrials.gov feed but 20 supporting publications, including one Phase II RCT and one Phase I/II combination trial.

Quick Overview

Item	Content
Original Indication	Metastatic Castration-Resistant Prostate Cancer (mCRPC), per literature evidence (no formal regulatory license data available)
Predicted New Indication	Female Breast Carcinoma
TxGNN Prediction Score	99.92%
Evidence Level	L2
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (Data Gap DG002). Based on information contained in the supporting literature, cabazitaxel is a taxane-class microtubule inhibitor structurally related to docetaxel, and it was FDA-approved in 2010 for use in combination with prednisone in taxane-refractory metastatic prostate cancer (TROPIC study). Its efficacy in that original indication has been proven, and mechanistically it may be applicable to breast cancer given the class effect of taxanes.

Taxanes (paclitaxel, docetaxel) are already standard-of-care components of breast cancer chemotherapy, and cabazitaxel was specifically engineered to have low affinity for the P-glycoprotein efflux pump, giving it activity against taxane/anthracycline-resistant tumor cell lines — including resistant MCF-7 breast cancer models described in the literature. This resistance-overcoming profile is the key pharmacological rationale connecting the original prostate cancer indication to the predicted breast cancer indication: both are settings where taxane-refractory disease is a major clinical problem.

The supporting evidence base spans a spectrum from an early-phase clinical combination trial and a randomized Phase II neoadjuvant trial in HER2-negative/triple-negative breast cancer, through pharmacology reviews on resistance mechanisms and dosing, to multiple preclinical nanoparticle-delivery studies aimed at improving cabazitaxel's poor solubility for breast tumor targeting — indicating active, ongoing translational interest in this indication.

Clinical Trial Evidence

Currently no related clinical trials registered

(Note: two literature-indexed clinical studies exist — a Phase II RCT and a Phase I/II dose-escalation trial — see Literature Evidence below, as they were not captured in the structured clinical_trials registry field.)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28768217	2017	RCT (Phase II)	European Journal of Cancer	GENEVIEVE trial: neoadjuvant cabazitaxel vs weekly paclitaxel compared, evaluating pathological complete response in operable TNBC/luminal B HER2-negative breast cancer
21339064	2011	Phase I/II Clinical Trial	European Journal of Cancer	Dose-escalation study of cabazitaxel + capecitabine in metastatic breast cancer after prior anthracycline/taxane; established MTD, safety, PK, and antitumor activity
33247980	2021	Review	British Journal of Clinical Pharmacology	Overview of taxane pharmacology (incl. cabazitaxel) and role of therapeutic drug monitoring-based dose adjustment
25416788	2015	Review	Molecular Cancer Therapeutics	Mechanisms of cabazitaxel resistance in taxane-resistant models, including MCF-7 breast cancer cells; less cross-resistance vs paclitaxel/docetaxel
26651178	2016	Review	Expert Opinion on Therapeutic Patents	Patent perspective on taxane anticancer agents, including cabazitaxel's FDA approval history
30521787	2019	Preclinical	Chemistry and Physics of Lipids	Cabazitaxel + thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer
33360926	2021	Preclinical	Colloids and Surfaces B: Biointerfaces	Cabazitaxel-loaded nanostructured lipid carriers (NLCs) designed and evaluated against breast cancer cell lines
34309357	2021	Preclinical	Bioconjugate Chemistry	Cyclic cell-penetrating peptide-targeted cabazitaxel delivery for prostate and breast cancer therapy
36918084	2023	Preclinical	Journal of Controlled Release	Redox-responsive nanomedicine co-delivering cabazitaxel and dasatinib to modulate tumor-stromal crosstalk in breast cancer
33753567	2021	Preclinical	Journal for ImmunoTherapy of Cancer	Cabazitaxel modulates tumor-associated macrophages to enhance CD47-targeted immunotherapy in triple-negative breast cancer

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Taxane class — microtubule-stabilizing agent)
Myelosuppression Risk	High — neutropenia is reported as the most common dose-limiting toxicity across taxane class studies, alongside peripheral neuropathy
Emetogenicity Classification	Low to moderate (typical of taxane-class agents)
Monitoring Items	CBC with differential (neutrophil count especially), liver function, peripheral neuropathy assessment
Handling Protection	Must follow cytotoxic drug handling regulations (hazardous drug precautions during preparation and administration)

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: One Phase II RCT (GENEVIEVE) and one Phase I/II combination trial provide direct clinical signal for cabazitaxel in breast cancer, reinforced by resistance-mechanism and pharmacology reviews plus an active stream of preclinical delivery-optimization research. However, cabazitaxel-specific breast cancer evidence remains limited to early/mid-phase trials (L2), and the drug is not currently marketed in Norway.

To proceed, the following is needed:

Formal mechanism of action (MOA) documentation from DrugBank or regulatory source
TFDA/Norwegian regulatory labeling, warnings, and contraindications (currently Data Gap, Blocking severity)
Drug-drug interaction data
Confirmation of whether more recent/later-phase cabazitaxel breast cancer trials exist beyond the identified Phase I/II and Phase II studies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.